atopic dermatitis ad epidemiology forecast insights

DelveInsight’s ‘Atopic Dermatitis (AD) - Epidemiology Forecast–2034’ report delivers an in-depth understanding of the disease, historical and forecasted Atopic Dermatitis (AD) epidemiology in the United States.

Geography Covered

• The United States

Study Period: 2021-2034

Atopic Dermatitis (AD) Understanding

Atopic Dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances.

AD presents different symptoms depending on the age of the person. Itching is the hallmark of AD; more than 85% of people with the condition experience this distressing symptom every day. The exact cause of AD is unknown. The basic understanding of AD is that inflammation results from compromised skin barrier leading to drier skin that is more prone to water loss and the entry of irritants. Thus, AD is caused by a complex interaction of immune dysregulation, epidermal gene mutations, and environmental factors that disrupt the epidermis causing intensely pruritic skin lesions.

There is currently no reliable biomarker that can distinguish the disease from other entities. However, the most commonly used biomarker is elevated total and/or allergen-specific serum IgE. Occasionally, patients carrying an AD diagnosis may display atypical clinical features, chronic dermatoses, infectious processes, and primary immunodeficiency may mimic the presentation leading to the differential diagnosis. Noninfectious dermatoses include contact dermatitis, seborrheic dermatitis, and psoriasis.

At present, there is no specific test for AD, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Diagnosis of AD is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis.

Atopic Dermatitis (AD) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Atopic Dermatitis (AD), Diagnosed Prevalent Population of Atopic Dermatitis (AD), Severity-specific Distribution of Atopic Dermatitis (AD) in Adults, Severity-specific Distribution of Atopic Dermatitis (AD) in Pediatric Population and Gender-specific Distribution of Atopic Dermatitis (AD) in Adults in the United States market from 2021 to 2034.

Atopic Dermatitis (AD) Detailed Epidemiology Segmentation

• The total prevalent population of AD in the United States was estimated to be 32,197,083 in 2020.
• The total diagnosed prevalent population of AD in the United States was estimated to be 25,091,967 in 2020.
• The prevalent population of AD in the United States is expected to increase at a CAGR of 0.58% during the study period 2021-2034.
• In the United States, the total number of adult cases of AD comprised of 5,684,566 males and 9,421,907 females in 2020.
• The total number of cases of mild AD were 9,065,394 in the United States, in 2020, as compared to the cases of moderate and severe AD with 4,365,771 and 1,661,712 cases respectively, in adults.
• In children, the total number of cases of mild AD were 6,690,281, in 2020, as compared to the cases of moderate and severe AD with 2,596,228 and 698,985 cases respectively, in the United States.

Scope of the Report

• The report covers the descriptive overview of Atopic Dermatitis (AD), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the historical and forecasted patient pool covering the United States.
• The report assesses the disease risk and burden and highlights the unmet needs of Atopic Dermatitis (AD).
• The report provides the segmentation of the disease epidemiology for the United States by Prevalent Population of Atopic Dermatitis (AD), Diagnosed Prevalent Population of Atopic Dermatitis (AD), Severity-specific Distribution of Atopic Dermatitis (AD) in Adults, Severity-specific Distribution of Atopic Dermatitis (AD) in Pediatric Population and Gender-specific Distribution of Atopic Dermatitis (AD) in Adults.

Report Highlights

• Ten Year Forecast of Atopic Dermatitis (AD)
• The United States Coverage
• Total prevalent population of Atopic Dermatitis (AD).
• Total diagnosed prevalent population of Atopic Dermatitis (AD).
• Delvelnsight has analysed gender-specific distribution of AD. As per the analysis, AD is more prevalent in females than in males.
• In addition, severity-specific data of AD was analyzed, according to which the adult and pediatric population of AD can be categorized as mild, moderate and severe AD. As per the DelveInsight estimates, it has been found that the mild form of AD included maximum cases, while minimum number of cases were found in severe form of AD in both the populations. This trend is clearly evident in the United States for the study period 2021-2034.

Analyst Comments

Various epidemiology studies and international surveys on the prevalence of AD have been conducted in the US. Data from these studies indicate that AD is a common skin disease in both children and adults, predominantly in the adult female population. Some studies have also indicated a three-fold increase in the past few decades.

Key Questions Answered

• What is the disease risk, burden and unmet needs of Atopic Dermatitis (AD)?
• What is the historical Atopic Dermatitis (AD) patient pool in the United States?
• What would be the forecasted patient pool of Atopic Dermatitis (AD) at the United States level?
• What will be the growth opportunities in the United States with respect to the patient population pertaining to Atopic Dermatitis (AD)?
• At what CAGR the population is expected to grow in the United States during the forecast period (2025-2034)?

Reasons to buy

The Atopic Dermatitis (AD) report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving in the United States Atopic Dermatitis (AD) market.
• Quantify patient share distribution in the United States for Atopic Dermatitis (AD).
• The Atopic Dermatitis (AD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Atopic Dermatitis (AD) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population